X4 Pharmaceuticals Outlines Mavorixafor Development Milestones
X4 said pivotal Phase 3 data are expected in Q1 2028, with potential U.S. approval in late 2028 or early 2029.
X4 said pivotal Phase 3 data are expected in Q1 2028, with potential U.S. approval in late 2028 or early 2029.